Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
XPC silencing in normal human keratinocytes triggers metabolic alterations that drive the formation of squamous cell carcinomas
Hamid Reza Rezvani, … , Frédéric Mazurier, David R. Bickers
Hamid Reza Rezvani, … , Frédéric Mazurier, David R. Bickers
Published December 1, 2010
Citation Information: J Clin Invest. 2011;121(1):195-211. https://doi.org/10.1172/JCI40087.
View: Text | PDF
Research Article Oncology

XPC silencing in normal human keratinocytes triggers metabolic alterations that drive the formation of squamous cell carcinomas

  • Text
  • PDF
Abstract

DNA damage is a well-known initiator of tumorigenesis. Studies have shown that most cancer cells rely on aerobic glycolysis for their bioenergetics. We sought to identify a molecular link between genomic mutations and metabolic alterations in neoplastic transformation. We took advantage of the intrinsic genomic instability arising in xeroderma pigmentosum C (XPC). The XPC protein plays a key role in recognizing DNA damage in nucleotide excision repair, and patients with XPC deficiency have increased incidence of skin cancer and other malignancies. In cultured human keratinocytes, we showed that lentivirus-mediated knockdown of XPC reduced mitochondrial oxidative phosphorylation and increased glycolysis, recapitulating cancer cell metabolism. Accumulation of unrepaired DNA following XPC silencing increased DNA-dependent protein kinase activity, which subsequently activated AKT1 and NADPH oxidase-1 (NOX1), resulting in ROS production and accumulation of specific deletions in mitochondrial DNA (mtDNA) over time. Subcutaneous injection of XPC-deficient keratinocytes into immunodeficient mice led to squamous cell carcinoma formation, demonstrating the tumorigenic potential of transduced cells. Conversely, simultaneous knockdown of either NOX1 or AKT1 blocked the neoplastic transformation induced by XPC silencing. Our results demonstrate that genomic instability resulting from XPC silencing results in activation of AKT1 and subsequently NOX1 to induce ROS generation, mtDNA deletions, and neoplastic transformation in human keratinocytes.

Authors

Hamid Reza Rezvani, Arianna L. Kim, Rodrigue Rossignol, Nsrein Ali, Meaghan Daly, Walid Mahfouf, Nadège Bellance, Alain Taïeb, Hubert de Verneuil, Frédéric Mazurier, David R. Bickers

×

Figure 1

Effects of XPC downregulation on mitochondrial metabolism and glycolysis.

Options: View larger image (or click on image) Download as PowerPoint
Effects of XPC downregulation on mitochondrial metabolism and glycolysis...
Glucose consumption and lactate production (A) as well as the total endogenous ATP levels and ATP levels produced by mitochondria (B) were measured at the indicated time points after transduction. The glucose uptake, lactate production, and the total endogenous and mitochondrial ATP levels by shCtrl-transduced cells were set to 100% at each time point. The results were then compared with the shCtrl and are expressed as the average percentage of shCtrl ± SD of 3 independent experiments. *P < 0.05 (black) for shXPC-transduced cells versus shCtrl-transduced cells; *P < 0.05 (purple) for XPC-KC versus control keratinocytes at the indicated time points. (C) The protein expression levels of XPC, ND1, COX3, GLUT1, HK-2, PFKPB-3, and G6PD were determined by Western blot at the indicated days after transduction. β-actin was used as a loading control. (D) The relative activity of complex IV of the mitochondrial respiratory chain was assessed. The mRNA levels of COX1 and COX3, ND1 and ND5 (E), HK-2 and PFKFB3, and GLUT1 and G6PD (F) were quantified by qRT-PCR. The results are shown as the average percentage of control ± SD of 3 independent experiments. (G) The mitochondrial network morphology in XPC-KC, shCtrl-, and shXPC-transduced keratinocytes was determined by microscopy using MitoTracker. Scale bars: 10 μM. (H) Length of mitochondrial tubules was measured in 50 cells (25 mitochondrial tubules per cell) per condition. Results are expressed as average percentage of mitochondrial tubule size distribution ± SD of 3 independent experiments. *P < 0.05 (black) for shXPC cells versus shCtrl-transduced cells. shCtrl, keratinocytes transduced with control shRNA; shXPC, keratinocytes transduced with shXPC; XPC-KC, keratinocytes isolated from XPC patients.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts